Search results

1693 results

Sorted by Date . Sort by Relevance

  1. The percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function, thyroid function tests, serum vitamin B12 and folate levels recorded up to 12 months before entering on to the register

    The percentage of patients with dementia (diagnosed on or after 1 April 2014) with a record of FBC, calcium, glucose, renal and liver function,...

  2. The percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent

    The percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in

  3. The percentage of women, on the register, prescribed emergency hormonal contraception 1 or more times in the preceding 12 months by the contractor who have received information from the contractor about long acting reversible methods of contraception at the time of or within 1 month of the prescription (Inherited)

    The percentage of women, on the register, prescribed emergency hormonal contraception 1 or more times in the preceding 12 months by the contractor who

  4. The committee also noted that the additional evidence exploring the relationship between radiological measures of bone defects (that is, the Rickets Severity Score and the Radiographic Global Impression of Change) and health-related quality of life would help to address several key uncertainties in the economic analysis.

    Recommendation ID HST8/2 Question The committee also noted that the additional evidence exploring the relationship between radiological

  5. In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed that further research into the treatment benefit of burosumab in young people aged 13 years and over would relieve some of the clinical uncertainty in an age group covered by the marketing authorisation.

    Recommendation ID HST8/1 Question In its evaluation of burosumab, the committee noted substantial uncertainty in several areas, and agreed

  6. Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum toxin type A injection using electrical localisation (electrostimulation orelectromyography) of muscles more clinically and cost effective than ultrasound-guided injections or clinical positioning for localisation of injections in treating focal spasticity in adults with cerebral palsy?

    Recommendation ID NG119/1 Question Method of botulinum toxin type A injection in treating focal spasticity:- Is guided botulinum toxin

  7. Research is recommended to address uncertainties about the claimed benefits of using Mepilex Border Heel and Sacrum dressings. This research should also explore issues such as:- the incidence of heel and sacrum pressure ulcers in NHS acute care settings- criteria for patient selection to reduce pressure ulcer incidence with Mepilex Border Heel and Sacrum dressings in addition to standard care.NICE will consider reviewing this guidance when substantive new evidence becomes available.

    Recommendation ID MTG40/1 Question Research is recommended to address uncertainties about the claimed benefits of using Mepilex Border